Carna Biosciences Inc (4572):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Carna Biosciences Inc (4572) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3504
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Carna Biosciences Inc (Carna) is a biotechnology company that discovers and develops drugs for the treatment of cancer and inflammatory diseases. The company offers products such as kinase proteins, biotinylated kinases, substrates, assay kits, protein substrates, inactive kinases, inactive-mutant kinases, pre-selected panels, crystal grade proteins and ready to use products to study kinases-molecule interactions, among others. Its kinase proteins include cytoplasmic tyrosine kinases, receptor tyrosine kinases, lipid kinases, serine and threonine kinases, among others. Carna offers services such as RPPA cell signaling analysis service, tyrosine kinase cell-based assay, co-crystallography, assay development and profiling services. The company serves its clients across Japan. Carna is headquartered in Kobe, Japan.

Carna Biosciences Inc (4572) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Carna Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Carna Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 9
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Carna Biosciences Acquires Cdc7/ASK Kinase Inhibitor from SBI Biotech 11
Partnerships 12
Evotec Enters into Partnership with Carna Biosciences 12
Carna Biosciences Enters into Development Agreement with Sumitomo Dainippon Pharma 13
Carna Biosciences Enters into Research Agreement with EpiBiome 14
SARomics Biostructures Enters into Distribution Agreement with Carna Biosciences 15
Netherlands Translational Research Center Enters Into Co-Marketing Agreement With Carna Biosciences 16
Merger 17
ProbeX to Merge with Carna Biosciences 17
Licensing Agreements 18
ProNAi Therapeutics Enters into Licensing Agreement with Carna Biosciences 18
Carna Biosciences Enters into Licensing Agreement with SBI Biotech 19
Acquisition 20
Carna Biosciences Announces Stock Exchange Ratio To Acquire ProbeX 20
Carna Biosciences Inc – Key Competitors 21
Carna Biosciences Inc – Key Employees 22
Carna Biosciences Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Aug 07, 2018: Carna Biosciences: Consolidated financial results for the second quarter of the year ending December 31, 2018 24
Nov 10, 2017: Consolidated Financial Results for the Third Quarter of the Year Ending December 31, 2017 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Carna Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Carna Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Carna Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 9
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Carna Biosciences Acquires Cdc7/ASK Kinase Inhibitor from SBI Biotech 11
Evotec Enters into Partnership with Carna Biosciences 12
Carna Biosciences Enters into Development Agreement with Sumitomo Dainippon Pharma 13
Carna Biosciences Enters into Research Agreement with EpiBiome 14
SARomics Biostructures Enters into Distribution Agreement with Carna Biosciences 15
Netherlands Translational Research Center Enters Into Co-Marketing Agreement With Carna Biosciences 16
ProbeX to Merge with Carna Biosciences 17
ProNAi Therapeutics Enters into Licensing Agreement with Carna Biosciences 18
Carna Biosciences Enters into Licensing Agreement with SBI Biotech 19
Carna Biosciences Announces Stock Exchange Ratio To Acquire ProbeX 20
Carna Biosciences Inc, Key Competitors 21
Carna Biosciences Inc, Key Employees 22
Carna Biosciences Inc, Subsidiaries 23

List of Figures
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Carna Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Carna Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Carna Biosciences Inc (4572):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Global Investment House KPSC:企業の戦略的SWOT分析
    Global Investment House KPSC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Heathrow Airport Holdings Ltd:企業の戦略的SWOT分析
    Heathrow Airport Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Sumo Group PLC (SUMO):企業の財務・戦略的SWOT分析
    Sumo Group PLC (SUMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Netflix, Inc.:企業の戦略・SWOT・財務情報
    Netflix, Inc. - Strategy, SWOT and Corporate Finance Report Summary Netflix, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Dr. Paul Lohmann GmbH & Co KGaA:企業の戦略・SWOT・財務分析
    Dr. Paul Lohmann GmbH & Co KGaA - Strategy, SWOT and Corporate Finance Report Summary Dr. Paul Lohmann GmbH & Co KGaA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Campine NV (CAMB):企業の財務・戦略的SWOT分析
    Campine NV (CAMB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Natrix Separations Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Natrix Separations Inc (Natrix), formerly Nysa Membrane Technologies, a subsidiary of Merck KGaA, is a supplier of single use and multi-cycle disposable chromatography products. The company offers NatriFlo HD-Q membrane adsorbers, an advanced material with a three-dimensional macroporous hyd …
  • Blue Label Telecoms Ltd (BLU):企業の財務・戦略的SWOT分析
    Blue Label Telecoms Ltd (BLU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Trex Company Inc (TREX):企業の財務・戦略的SWOT分析
    Trex Company Inc (TREX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Yanchang Petroleum International Ltd (346):企業の財務・戦略的SWOT分析
    Yanchang Petroleum International Ltd (346) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Sentien Biotechnologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Sentien Biotechnologies Inc (Sentien) is a clinical stage biotechnology company that develops novel delivery approaches to cell therapy. The company’s lead product SBI-101 is used for the treatment of patients with severe acute kidney injury (AKI). Its Sentinel is designed to enable controll …
  • Exponent Inc (EXPO):企業の財務・戦略的SWOT分析
    Summary Exponent Inc (Exponent), formerly Failure Analysis Associates Inc, is an engineering and scientific consulting company that provides technical solutions. The company provides engineering services in biomechanics, buildings and structures, biomedical engineering, civil engineering, electrical …
  • CEZ, AS (CEZ)-エネルギー分野:企業M&A・提携分析
    Summary CEZ, a.s. (CEZ) is an integrated energy conglomerate that extracts and sells coal; generates and distributes electricity and heat; and trades in electricity, natural gas, and other commodities. It generates electricity from nuclear, coal, gas, hydro, solar, wind, and biogas sources. The comp …
  • City Developments Ltd:戦略・SWOT・企業財務分析
    City Developments Ltd - Strategy, SWOT and Corporate Finance Report Summary City Developments Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Specialist Investment Properties PLC:企業の戦略・SWOT・財務分析
    Specialist Investment Properties PLC - Strategy, SWOT and Corporate Finance Report Summary Specialist Investment Properties PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Chubu Electric Power Co Inc:発電所・企業SWOT分析
    Chubu Electric Power Co Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key e …
  • Eureka Forbes Limited:企業の戦略的SWOT分析
    Eureka Forbes Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Biosensors International Group Ltd:企業の戦略的SWOT分析
    Biosensors International Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Hindustan ZInc Ltd:戦略・SWOT・企業財務分析
    Hindustan ZInc Ltd - Strategy, SWOT and Corporate Finance Report Summary Hindustan ZInc Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Allianz Global Corporate & Specialty Singapore
    Allianz Global Corporate & Specialty Singapore - Strategy, SWOT and Corporate Finance Report Summary Allianz Global Corporate & Specialty Singapore - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆